Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis

International Journal of Cancer

Volumn 69, Issue 2, 1996, Pages 135-141

  Seshadri, Ram ^a,d   Leong, Anthony S Y ^b   Mccaul, Kieran ^c   Firgaira, Frank A ^a   Setlur, Vittal ^a   Horsfall, David J ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^c South Australian Health Commission   (Australia)

^d FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS;

ADULT; BREAST NEOPLASMS; CELL DIVISION; EXONS; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; GENES, P53; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROGNOSIS; RISK;

EID: 0030002609     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960422)69:2<135::AID-IJC12>3.0.CO;2-8     Document Type: Article

References (29)

1. ALLRED, D.C, CLARK, G.M., ELLEDGE, R., FLOCA, S.A.W., BROWN, R.W., CRAMNESS, G.C, OSBORNE, C.K. and MCGUIRE, W.L., Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. nat. Cancer Inst., 85, 200-206(1993).
2. ALTMAN, D.G., LAUSEN, B., SAUERBREI, W. and SCHUMAKER, M., Dangers of using "optima!" cutpoints in the evaluation of prognostic factors. J. nat. Cancer Inst., 86, 829-835 (1994).
3. BARNES, D.M., DUBLIN, E.A., FISHER, C.J., LEVISON, D.A. and MILLFS, R.R., Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum, Paihol. 24, 469-476 (1993).
4. BERGH, J., NORBERG, T., SJOGREN, S., LINDGREN, A. and HOLMBERG, L., Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med. 1, 1029-1034 (1995).
5. CATTORETTI, G., BECKER, M.H.G., KEY, G., DUCHROW, M., SCHLUTER, C., GALLE, J. and GERDES, J., Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB 3) detect proliferating cells in microwave processed formalin-fixed paraffin sections. J. Pathol., 168, 357-363 (1992).
6. CALLFFI. M., TEAGLE, M.W., JENSEN, R.A., VNENCAK-JONES, C.L., DUPONT, W.D. and PARL, F.F., p53 mutations and steroid receptor status in breast cancer. Cancer. 73, 2147-2156 (1994).
7. CHANG, F., SYRJANEN, S. and SYRJÄNEV K., Implications of p53 tumor-suppressor gene in clinical oncology. J. clin. Oncol., 13, 1009-1022 (1995).
8. Cox. D.R. and HINKLEY, D.V., Theoretical statistics, pp. 314-317, Chapman and Hall, London (1974).
9. GAGLIA, P., BERNARDI, A., VENESIO, T., CALDAROLA, B., LAURO, D. and CAPPA, A.P., Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: its prognostic value on short-term recurrence. Europ. J Cancer, 29, 1501-1502 (1993).
10. GASPARINI, G., BORACCHI, P., VERDERIO, P. and BEVILACOUA, P., Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. Int. J. Cancer, 57, 822-829 (1994a).
11. GASPARINI, G., WIEDNER, N., BEVILACQUA, P., MALUTA, S., DALLA PALMA, P., CAFEFO. O., BARBERESCHI. M., BORACCHI, P., MARUBINI, E. and POZZA, F., Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast cancer. J. clin. Oncol., 12, 454-466 (1994b).
12. HALL, P.A. and LANE, D.P., p53 in tumour pathology: can we trust immunochemistry? - revisitedl J. Pathol., 172, 1-4 (1994).
13. HORSFALL, D.J., TILLEY, W.D., ORELL, S.R., MARSHALL, V.R. and CANT. E.L.M., Relationship between ploidy and steroid hormone receptors in primary breast cancer. Brit. J. Cancer, 53, 23-28 (1986).
14. ISOLA, J., VISAKORPI, T., HOLLI, K. and KALLIONIEMI, O.-P., Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J. nat. Cancer Inst., 84, 1109-1114 (1992).
15. JACQUEMIER, J., MOLES, J.P., PENAULT-LLORCA, F., ADELAIDE, J., TORRENTL, M., VIENS, P., BIRNBAUM, D. and THEILLET, C., p53 immunochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Brit. J Cancer, 69, 846-852 (1994).
16. LEONG, A.S.-Y. and MILIOS, J., An assessment of the efficacy of the microwave antigen-retrieval procedure on a ranee of tissue antigens. Appl. Immunohistochem., 1, 267-274 (1993).
17. MARKS, J.R., HUMPHREY, P.A., WU, K. and BERRY. D., Overexpression of p53 and HER-2/neu protein as prognostic markers in early stage breast cancer. Ann. Surg., 219, 332-341 (1994).
18. MURAKAMI, Y., HAYASHI, K. and SEKIYA, T., Detection of aberrations of p53 alleles and the gene transcript in human tumour cell lines by single strand conformation polymorphism analysis. Cancer Res., 51, 3356-3361 (1991).
19. OSBORNE, C.K., Prognostic factors for breast cancer: have they met their promise? Editorial. J. clin. Oncol., 10, 679-682 (1992).
20. RAILO, M., NORDLING, S., VON BOGUSLAWSKY, K., LEIVONEN, M., KYLLONEN, L. and VON SMITTEN, K., Prognostic value of Ki-67 immunolabelling in primary operable breast cancer Brit. J. Cancer, 68, 579-583 (1993).
21. ROSEN, P.P., LESSER, M.L., ARROYA, C.D., CRANOR, M., BORGEN, P. and NORTON, L., p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J. clin. Oncol, 13, 821-830 (1995).
22. RUDAS, M., GNANT, M.F., MITTLBOCK, M., NEUMAYER, R., KUMMER, A., JAKESZ, R., REINER, G. and REINER. A., Thymidine labelling index and Ki-67 growth fraction in breast cancer. Breast Cancer Res. Treat., 32, 165-175 (1994).
23. SCHROEDER, J.J., SCHAID, D.J., KOVACH, J.S. and SOMMER, S.S., Novel pattern of p53 mutation in breast cancer from Austrian women. J. clin. Invesr., 95, 686-689 (1995).
24. SESHADRI, R., FIRGAIRA, F., HORSFALL, D.J., McCALL, K., SETLUR, V. and KITCHEN, P., Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J. clin. Oncol., 11, 1936-1942 (1993).
25. TAYLOR. C.R., SHI, S.-R., CHAIWUN, B., YOUNG, L., IMAM, S.A. and COTE, R.J., Strategies for improving the immunochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen revealed by antigen retrieval techniques. Hum. Pathol., 25, 263-270 (1994).
26. THOR, A.D., MOORE, D.H., II, EDGERTON, S.M., KAWASAKI, E.S., REIHSAUS, E., LYNCH, H.T., MARCUS, J.N., SCHWARTZ, L., CHEN, L.-C., MAYALL, B.H. and SMITH, H.S., Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. nat. Cancer Inst., 84, 845-855 (1992).
27. VERONESE, S.M., GAMBACORTA, M., GOTTARDI, O., SCANZI, F., FERRARI, M. and LAMPERTICO, P, Proliferation index as a prognostic marker in breast cancer. Cancer, 71, 3926-3931 (1993).
28. WEIKEL, W., BECK, T., MITZE, M. and KNAPSTEIN. P.G., Immunohistochemical evaluation of growth fractions in human breast cancer using monoclonal antibody Ki-67. Breast Cancer Res. Treat., 18, 149-154 (1991).
29. WILTSCHKE, C., KINDAS-MUEGGE, I., STEININGER, A., REINER, A., REINER, G. and PREIS, P.N., Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients. J. Cancer. Res. clin. Oncol. 120, 737-742 (1994).